DX 182Alternative Names: DX-182
Latest Information Update: 12 Sep 2003
At a glance
- Originator Dyax
- Developer Dyax Corp.
- Class Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 18 Jul 2001 Preclinical development for Thrombosis (daignosis) in USA (unspecified route)